Travere Therapeutics: cross-border access for the specialty portfolio

Quick orientation

Travere Therapeutics, Inc. is a US biopharmaceutical company headquartered in San Diego, California, focused on rare kidney diseases and metabolic rare diseases. The company developed the first non-immunosuppressive therapy approved by the FDA for IgA nephropathy (Filspari) and operates a focused commercial organisation around its rare-disease franchise. Travere trades on NASDAQ as TVTX. FDA approval scale spans Filspari, Thiola/Thiola EC (tiopronin) for cystinuria, and Chenodal (chenodeoxycholic acid) for cerebrotendinous xanthomatosis and other indications.

Travere portfolio in cross-border NPP scope

Filspari (sparsentan) is an FDA-approved oral dual endothelin and angiotensin II receptor antagonist for adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression (FDA accelerated approval February 2023; traditional approval September 2024 following confirmatory data). Oral dosing, once daily. US list pricing is approximately US$10,000 per month. Filspari is the first non-immunosuppressive therapy with a glomerular kidney disease indication that targets both endothelin and angiotensin II pathways. Confirmatory data showed an effect on kidney function decline relative to standard renin-angiotensin system blockade.

Thiola and Thiola EC (tiopronin) are FDA-approved oral therapies for the treatment of cystinuria, an inherited disorder of amino acid transport that causes recurrent kidney stones. Thiola is taken orally multiple times daily as a reducing agent to lower urinary cystine.

Chenodal (chenodeoxycholic acid) is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX), an ultra-rare lipid storage disorder. Cholbam (cholic acid) is approved for bile acid synthesis disorders due to single enzyme defects.

Travere's pipeline includes pegtibatinase for homocystinuria and earlier-stage candidates. These are investigational and not in NPP scope.

Why patients route through cross-border NPP

Filspari is the highest-volume cross-border NPP demand driver in the Travere portfolio. IgA nephropathy is the most common primary glomerular kidney disease worldwide and is particularly prevalent in East Asian and South Asian populations. The condition progresses to end-stage kidney disease in a substantial fraction of patients over decades. Filspari is the first FDA-approved non-immunosuppressive therapy specifically indicated for IgAN at risk of rapid progression. Outside the United States, Filspari is approved in the European Union under the trade name Filspari with a similar indication, but country-by-country reimbursement and stocking remain uneven across the GCC, India, Turkey, and most of MENA and Southeast Asia. Confirmed-IgAN patients with elevated urine protein and treating-nephrologist prescription routinely seek cross-border NPP supply.

Thiola for cystinuria addresses an ultra-rare inherited metabolic condition. The standard alternative therapy, D-penicillamine, has greater toxicity, and Thiola/Thiola EC is generally preferred where available. Confirmed-cystinuria patients with documented recurrent stone formation route through cross-border NPP where local supply is unavailable.

Chenodal for CTX is similarly niche: CTX is ultra-rare (estimated incidence one in 50,000 to 70,000 worldwide), and chenodeoxycholic acid replacement is the disease-modifying therapy with strong evidence for reducing neurological progression.

Common cross-border destinations

The highest-frequency NPP destinations for Travere products from US-approved inventory are India, the United Arab Emirates, Saudi Arabia, Qatar, and Turkey. Nephrology centers for Filspari (with concentration in South Asian patient populations where IgAN incidence is high), urology and metabolic centers for Thiola, and rare-disease referral centers for Chenodal in Mumbai, Bangalore, Delhi, Hyderabad, Dubai, Riyadh, and Istanbul drive most inbound referrals.

Manufacturer engagement posture

Reserve Meds coordinates Travere-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with Travere Therapeutics. Our role is patient-facing coordination on behalf of named individual patients with a verified prescription. For Travere medical affairs or commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Travere product request, Reserve Meds coordinates: prescription verification with the treating physician (nephrologist for Filspari and Thiola; metabolic specialist for Chenodal and Cholbam); diagnostic documentation review (renal biopsy or clinical IgAN criteria for Filspari; cystine excretion documentation for Thiola; genetic confirmation for CTX); DSCSA serialized chain-of-custody from Travere through licensed US wholesalers to the named patient; ambient shipping with appropriate packaging; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients with a treating-physician prescription for a Travere product can begin a request now. Start a Filspari request ›

Next step for Travere teams

Travere Therapeutics medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.